Proxy Results Form 8 K

On October 29, 2024, at the closing of the Common Stock Private Placement (as such term is defined in Item 8.01), Eterna Therapeutics Inc. (the "Company," "we," "us," or "our") entered into a registration rights agreement with the investors in the Common Stock Private Placement. Under the terms of that agreement, we agreed to file a registration statement with the Securities and Exchange Commission on or prior to November 5, 2024 to register for resale the shares of our common stock issued at, and the shares of our common stock issuable upon exercise of the pre-funded warrants issued at, the closing of the Common Stock Private Placement. We are required to have such registration statement declared effective within 45 days after filing, or 60 days after filing if the registration statement is subject to a full review.